Johnson & Johnson JNJ

Johnson & Johnson es una empresa holding que se dedica a la investigación y desarrollo, fabricación y venta de una variedad de productos en el campo de la salud. Opera a través de tres segmentos: Consumo, Farmacéutico y Dispositivos Médicos. Su enfoque principal son los productos relacionados con la salud y el bienestar humano. El segmento de Consumo incluye una variedad de productos utilizados en el cuidado del bebé, cuidado bucal, cuidado de la piel, productos farmacéuticos de venta libre, salud de la mujer y cuidado de heridas. El segmento Farmacéutico se enfoca en cinco áreas terapéuticas, incluyendo inmunología, enfermedades infecciosas, neurociencia, oncología y enfermedades cardiovasculares y metabólicas. El segmento de Dispositivos Médicos incluye una variedad de productos utilizados en los campos de ortopedia, cirugía, cardiovascular, cuidado de la diabetes y cuidado de la visión. Sus instalaciones de investigación se encuentran en Estados Unidos, Bélgica, Brasil, Canadá, China, Francia, Alemania, India, Israel, Japón, Países Bajos, Singapur, Suiza y Reino Unido.

Con 4 acciones de JNJ (USD 1.030,03) habrías recibido USD 21,12 en dividendos en los últimos 12 meses.

• Zacks Investment Research 1 oct

  ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?

  AbbVie's stock has gained 25.4% over six months, driven by strong growth from Skyrizi and Rinvoq, which are expected to generate over $31 billion in combined 2026 sales. The company is successfully navigating Humira's patent expiry through new immunology and neuroscience products. However, challenges include Humira biosimilar erosion, slowing oncology sales, and weakness in the Aesthetics business. Analysts recommend holding the stock (Zacks Rank #3) as long-term prospects remain intact with expected 10% revenue growth in 2026.

  

• Zacks Investment Research 30 sept

  Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now

  Johnson & Johnson (JNJ) is highlighted as a compelling dividend investment opportunity for income investors. The company currently offers a 2% dividend yield with an annualized dividend of $5.36, up 4.3% year-over-year. With a conservative 49% payout ratio and expected earnings growth of 7.60% in 2026, JNJ demonstrates solid fundamentals. However, the stock carries a Zacks Rank of #3 (Hold), suggesting a neutral outlook despite its strong dividend credentials.

  

• GlobeNewswire Inc. 30 sept

  Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

  The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.

  

• Zacks Investment Research 29 sept

  Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

  Johnson & Johnson stock declined 1.58% on September 29, 2026, underperforming the broader market. The company is expected to report earnings on October 13, 2026, with projected EPS of $2.96 (5.71% YoY growth) and revenue of $25.36 billion. JNJ currently holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 23.43, trading at a premium to its industry average.

  

• Zacks Investment Research 29 sept

  Defensive Dividends: 3 Companies Investors Can Rely On

  Three Dividend King stocks—Johnson & Johnson (JNJ), Coca-Cola (KO), and AbbVie (ABBV)—have each increased dividends for at least 50 consecutive years, with JNJ surpassing 60 years. All three have outperformed the S&P 500 in 2026 and offer yields between 2.0-2.6%, making them attractive for income-focused investors seeking defensive, stable dividend payers.